Selvita to Present Data From Multiple Oncology Programs at AACR 2019 Annual Meeting

Monday, March 4, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

KRAKOW, Poland, March 4, 2019 /PRNewswire/ -- Selvita (WSE: SLV), a clinical stage drug discovery and development company

engaged in the research and development of novel cancer therapies, today announced that data from multiple Selvita oncology programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place March
29 to April 3, 2019
, in Atlanta. Data presented will include results from the SEL120, CDK8 kinase inhibitor program as well as data from small-molecule STING agonist and dual A2A/A2B adenosine receptors antagonist programs.

Details of the poster presentations are as follows:

Presentation: "SEL120, a potent and specific inhibitor of CDK8 induces complete remission in human patient derived xenograft models of acute myeloid leukemia" Abstract Number: 1306 Session: Novel Targets and Pathways Date and Time: Monday, April 1, 8:00 AM - 12:00 PM

Presentation: "Novel dual A2A A2B adenosine receptor antagonists for cancer immunotherapy: in vitro and in vivo characterization" Abstract Number: 4135 Session: Novel Immunomodulatory Agents 2 Date and Time: Tuesday, April 2, 1:00 PM - 5:00 PM

Presentation: "Discovery and characterization of next-generation small molecule direct STING agonists" Abstract Number: 4983 Session: Immunomodulators and Response to Therapy Session Date and Time: Wednesday, April 3, 8:00 AM - 12:00 PM

Presentations will be located at the Georgia World Congress Center, Exhibit Hall B. Additional information is available at on the AACR conference website at http://www.aacr.org.

About Selvita

Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets. SEL24 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.

Contact:

Julia Balanova (investors) +1-646-378-2936     jbalanova@troutgroup.com 

Rich Allan (media) +1-646-378-2958 rallan@troutgroup.com 

Malgorzata Syjud (corporate)+48-660-797-362 malgorzata.syjud@selvita.com

 

Cision View original content:http://www.prnewswire.com/news-releases/selvita-to-present-data-from-multiple-oncology-programs-at-aacr-2019-annual-meeting-300805757.html

SOURCE Selvita



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store